Status:
UNKNOWN
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
Lead Sponsor:
Histogen
Collaborating Sponsors:
Gleneagles CRC Pte Ltd.
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
21-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men. HSC will be injected intradermally in the...
Detailed Description
HSC consists of proteins secreted by human dermal cells under proprietary culture conditions that include reduced oxygen and bioreactors. Under these conditions, the cells secrete soluble proteins tha...
Eligibility Criteria
Inclusion
- Male, ages 21-65 years.
- A healthy scalp with no cutaneous disorder.
- Subject should be in good general health.
- Male subjects must be classified 3 Vertex, 4, 4A (if large enough), 5, 5A, or 6 under the Norwood-Hamilton Classification for Male Pattern Hair Loss (See Appendix 1).
- Subject must be Fitzpatrick Type I, II, III and IV skin pigmentation (See Appendix 2). Type IV is acceptable however Type I-III is preferable.
- Willing and able to comply with scheduled visits (Total: 7 visits in 48 weeks)
- Willing to maintain the same hair style during the study period.
- Willing to have a total of four microscopic dot tattoos. Two tattoos per treatment site (one in the center and one on the edge) of the two target regions of the scalp at miniaturization zone.
- Willing to have 2 cm2 hairs clipped at treatment areas.
- Willing to forgo the use of scalp products, including dye, throughout the study except for study related dye.
- Willing to use a mild, a non-ionic shampoo throughout the course of the study.
Exclusion
- History of keloid formation or hyperpigmentation.
- A history of any acute or chronic illness that in the opinion of the investigators might confound the results of the study including some drugs or medications.
- Active skin diseases (e.g. eczema, atopic dermatitis, psoriasis, skin cancer, sun damaged skin with actinic keratosis on scalp, etc.).
- Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted). Two 81 mg or one 325 mg aspirin per day is also acceptable.
- Use of topical drugs or other cosmetics on the scalp.
- Immunological disorders such as HIV positive, alopecia areata, and systemic lupus erythematosus.
- Participation in any clinical study within the last four weeks.
- Moderate or severe seborrheic dermatitis of scalp.
- Damaged skin in or around test sites including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site.
- Use of OTC (over-the-counter) or prescriptive topical or hair treatments, as well as hair transplantation surgery during the last 6 months. This includes Minoxidil 2% or 5% and/or Finasteride 1mg or any 5alpha-reductase inhibitors.
- Currently using hair system or wig.
- Presence of hair transplants or scalp surgery.
- History of allergy or intolerance to lidocaine and/or epinephrine.
- Use of hair dye (not study related) during the study duration.
- Any condition for which the Investigator determines that the subject could be placed under undue risk.
- Reported history of allergy or intolerance to bovine proteins.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT01501617
Start Date
December 1 2011
End Date
December 1 2012
Last Update
January 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Medical City
Pasig, Manila, Philippines